INVESTIGADORES
DE MIGUEL Natalia
artículos
Título:
The T. vaginalis homolog of macrophage migration inhibitory factor induces prostate cell growth, invasion and inflammatory responses
Autor/es:
OLIVIA TWU; DANIELE DESSI; ANH VU; FRANCES MERCER; GRANT C. STEVENS ; NATALIA DE MIGUEL; PAOLA RAPPELLI; ANNA RITA COCCO; ROBERT T CLUBB ; PIER LUIGI FIORI; PATRICIA J. JOHNSON
Revista:
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Editorial:
NATL ACAD SCIENCES
Referencias:
Lugar: Washington DC, USA; Año: 2014
ISSN:
0027-8424
Resumen:
The human-infective parasite Trichomonas vaginalis causes the most prevalent non-viral sexually transmitted infection worldwide. Infections in men may result in colonization of the prostate and is correlated with increased risk of aggressive prostate cancer. We have found that T. vaginalis secretes a protein (TvMIF) that is 47% similar to human macrophage migration inhibitory factor (HuMIF), a pro-inflammatory cytokine. As HuMIF is reported to be elevated in prostate cancer and inflammation plays an important role in the initiation and progression of cancers, we have explored a role for TvMIF in prostate cancer. Here we show that TvMIF has tautomerase activity, inhibits macrophage migration, and is proinflammatory. We also demonstrate that TvMIF binds the human CD74 MIF receptor with high affinity, comparable to that of HuMIF, which triggers activation of ERK, Akt and BAD phosphorylation at a physiologically relevant concentration (1 ng/mL, 80 pM). TvMIF increases the in vitro growth and the invasion through matrigel of benign and prostate cancer cells. Sera from patients infected with T.vaginalis are reactive to TvMIF, especially in males. The presence of anti-TvMIF antibodies indicates that TvMIF is released by the parasite and elicits host immune responses during infection. Together, these data indicate that chronic T. vaginalis infections may result in TvMIF-driven inflammation and cell proliferation thus triggering pathways that contribute to the promotion and progression of prostate cancer.